Last $260.49 USD
Change Today +1.58 / 0.61%
Volume 796.3K
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 5:20 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

shire plc-adr (SHPG) Snapshot

Open
$259.36
Previous Close
$258.91
Day High
$262.32
Day Low
$259.24
52 Week High
09/17/14 - $262.32
52 Week Low
10/9/13 - $113.59
Market Cap
51.2B
Average Volume 10 Days
1.0M
EPS TTM
--
Shares Outstanding
196.5M
EX-Date
09/3/14
P/E TM
--
Dividend
$0.23
Dividend Yield
0.24%
Current Stock Chart for SHIRE PLC-ADR (SHPG)

shire plc-adr (SHPG) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

5,338 Employees
Last Reported Date: 02/24/14
Founded in 1986

shire plc-adr (SHPG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2013.

shire plc-adr (SHPG) Key Developments

Shire plc Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application for Vyvanse Capsules (CII) for Adults with Binge Eating Disorder

Shire plc announced that the US Food and Drug Administration (FDA) has accepted for filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) as a treatment for adults with binge eating disorder (BED). The FDA is expected to provide a decision in February 2015, based on the anticipated Prescription Drug User Fee Act (PDUFA) action date. Vyvanse is a prescription medicine currently only approved for Attention-Deficit/Hyperactivity Disorder (ADHD). Vyvanse should only be used to treat ADHD. Vyvanse is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep in a safe place to prevent misuse and abuse. Selling or sharing Vyvanse may harm others and is illegal. Shire is seeking approval for Vyvanse as a treatment option for adults with BED based on the results of two identically designed randomized placebo-controlled Phase 3 studies evaluating the efficacy and safety of Vyvanse versus placebo.

GlaxoSmithKline and Shire Looking To Acquire Tekmira Pharmaceuticals

GlaxoSmithKline plc (LSE: GSK) and Shire plc (LSE:SHP) are rumoured to be eyeing Tekmira Pharmaceuticals Corporation (TSX: TKM) according to Daily Mail. Tekmira Pharmaceuticals is developing an experimental treatment for the deadly ebola virus which has already claimed lives of more than 1,000 people in Africa.

Shire plc and ArmaGen Sign Licensing Agreement for Treatment of Hunter Syndrome

Shire plc and ArmaGen announced worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy, or ERT, for the potential treatment of both the central nervous system, or CNS, and somatic manifestations in patients with Hunter syndrome, or MPS II. Under the terms of the agreement, Shire will obtain worldwide commercialization rights for AGT-182 in exchange for payments of approximately $225 million to ArmaGen, including an initial upfront payment of $15 million in cash and equity, an additional equity investment, R&D funding, development milestones and sales milestones, in addition to royalty payments. As part of the agreement, ArmaGen will be responsible for conducting and completing the Phase I/II study which it expects to initiate before the end of 2014, after which point Shire will be responsible for further clinical development, including phase III trials, and commercialization.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $260.49 USD +1.58

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $237.09 USD -1.67
Allergan Inc/United States $170.04 USD -0.16
Celgene Corp $92.26 USD -0.31
CSL Ltd A$72.37 AUD -0.23
Valeant Pharmaceuticals International Inc C$134.09 CAD +0.06
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 31.2x
Price/Sales 9.4x
Price/Book 8.2x
Price/Cash Flow 46.3x
TEV/Sales 9.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.